Open Beta
MetriLume

US marketsBVS

SEC-sourced researchBeta

BVS

Bioventus Inc.

Company comparison ↗

Data passport

CIK
0001665988
Exchange
Nasdaq
Business activity
Surgical & Medical Instruments & Apparatus · SIC 3841
Financial inputs
6/6
Filing date
Nov 13, 2026
SEC registry record
Operating company

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2023: 512,345,000.0000 USD; December 2024: 573,280,000.0000 USD; December 2025: 568,087,000.0000 USD573.3M USD0 USD0December 2023December 2024December 2025
BVS · Exact amounts and source periods · USD
Period endRevenueFiling date
December 2023512,345,000.0000Mar 5, 2026
December 2024573,280,000.0000Mar 5, 2026
December 2025568,087,000.0000Mar 5, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 2025568,087,000.000022,732,000.000074,673,000.0000683,559,000.0000455,112,000.0000Mar 5, 2026
December 2024573,280,000.0000-36,125,000.000038,795,000.0000727,956,000.0000542,352,000.0000Mar 5, 2026
December 2023512,345,000.0000-156,230,000.000015,344,000.0000——Mar 5, 2026

Explainable fundamental score

Five equally weighted components based on SEC financial inputs. No price inputs or personal investment preferences.

63/100
Profitability58
Growth49
Balance sheet33
Cash generation76
Data coverage100

Component weight: 20% · Minimum data coverage: 50% · Missing component value: 50/100

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$568.09MJan 1, 2025 – Dec 31, 2025Mar 5, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$573.28MJan 1, 2024 – Dec 31, 2024Mar 5, 202610-K
Net incomeNetIncomeLoss$22.73MJan 1, 2025 – Dec 31, 2025Mar 5, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities$74.67MJan 1, 2025 – Dec 31, 2025Mar 5, 202610-K
Total assetsAssets$683.56MDec 31, 2025Mar 5, 202610-K
Total liabilitiesLiabilities$455.11MDec 31, 2025Mar 5, 202610-K

New filings

Explore methodology ↗